This paper describes the need for developing new antimicrobial drugs and outlines techniques used in the developmental process for new drugs. The second section details some of the newer antimicrobial agents that have been launched recently and those that are currently under development.
Adcock H.(2009) Clinical developments in2008. The Pharmaceutical Journal282: 25-8.
2.
Anon (2005) Bacteriophages - the new antibiotics?Hospital Pharmacist12: 342-4.
3.
Anon (2006a) FIP Congress 2006 - Nanotechnology: current and potential applications in drug delivery systems . The Pharmaceutical Journal277(Suppl): F31.
4.
Anon (2006b) Potential new target for RNA-binding antibiotics identified. The Pharmaceutical Journal277: 729.
5.
Anon (2006c) Novel class of antibiotics identified. The Pharmaceutical Journal276: 585.
6.
Anon (2008a) Credit crisis will hit drug development. The Pharmaceutical Journal281: 498.
7.
Anon (2008b) What role for tigecycline in infections?Drug and Therapeutics Bulletin46(8): 62-4.
8.
Anon (2008c) Retapamulin (Altabax) - a new topical antibiotic. The Medical Letter on Drugs and Therapeutics50(1280): 13-15.
9.
Anon (2009a) Not enough being done to develop new antibiotics despite increasing burden of resistance. The Pharmaceutical Journal283:320.
10.
Anon (2009b) Advanced purchase deals could lead to new antibiotics. The Pharmaceutical Journal282: 368.
11.
Anon (2009c) Vision of going from sea to bedside. The Pharmaceutical Journal283: 369.
12.
Basilea Pharmaceutica (2009) FDA accepts for review the Complete Response submission to ceftobiprole NDA (Press Release). http://hugin.info/134390/R/1338502/319382.pdf (accessed 11 March 2010).
13.
Bogdanovich T., Ednie LM, Shapiro S., Appelbaum PC ( 2005) Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrobial Agents and Chemotherapy49(10): 4210-19.
14.
Bryan J. ( 2005) Race to find new vaccine production techniques in fight against influenza. The Pharmaceutical Journal275: 543-4.
15.
Buenz EJ, Bauer BA, Johnson HE, Tavana G., Beekman EM, Frank KL, Howe CL ( 2006) Searching historical herbal texts for potential new drugs . BMJ333: 1314-15.
16.
Eiland EH, Gatlin D. ( 2008) Forecast of antibiotic development in an era of increasing bacterial resistance. Journal of Pharmacy Practice21(5): 313-8.
17.
Leonard SN, Rybak MJ ( 2008) Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram positive infections. Pharmacotherapy28(4): 458-68.
18.
Moberley T.( 2007) Why the UK must continue to nurture skills required for drug development. The Pharmaceutical Journal279: 557.
19.
Mycamine Summary of Product Characteristics ( 2009) Electronic Medicines Compendium. http://emc.medicines.org.uk/searchresults.aspx?term=Mycamine&searchtype=QuickSearch (accessed 11 March 2010).
20.
Seaton RA(2009) Skin and soft tissue infection: focus on methicillinresistant S aureus . Clinical Pharmacist1: 23-8.
21.
Slover CM, Rodvold KA, Danziger LH ( 2007) Tigecycline: a novel broad-spectrum antimicrobial. The Annals of Pharmacotherapy41(6): 965-72.
22.
Todd A.,A nderson R., Groundwater PW ( 2009b) Rational drug design - identifying and characterising a target. The Pharmaceutical Journal283: 19-20.
23.
Todd A., Worsley AJ, Anderson RJ, Groundwater PW(2009a) Current research and development into new antibacterial agents. The Pharmaceutical Journal283: 359-60.
24.
Wang L. ( 2008) FIP 2008: What is happening in the world of vaccine development and why. The Pharmaceutical Journal281: F14.
25.
Wicks SR ( 2000) Careers and development in a growing industrial sector . The Pharmaceutical Journal264: 150-1.
